Feb. 24 COVID Quick Takes: China reviewing CanSino’s vaccine; plus AZ’s vaccine in Ghana, NIH’s ‘Long COVID’ initiative, Celltrion and more
CanSino Biologics Inc. (HKEX:6185) said China’s National Medical Products Administration is reviewing its application for conditional authorization of Convidecia (Ad5-nCoV), its vaccine for COVID-19. In a regulatory filing, the company said Phase III data showed that Convidecia was 65.28% effective at preventing all symptomatic COVID-19 infection 28 days after administration of a single dose, and 90.07% effective at preventing severe disease at the same time point.
AstraZeneca vaccine arrives in Africa under COVAX
The World Health Organization said 600,000 doses of COVID-19 Vaccine AstraZeneca (AZN1222) arrived in Ghana, representing the first country outside of India to receive the vaccine under the COVAX global distribution program. The Serum Institute of India, which holds a license to the vaccine from AstraZeneca plc (LSE:AZN; NYSE:AZN), shipped the doses; another delivery is due this week in Côte d’Ivoire...